The Most Important Question About Radiotherapy in Prostate Cancer Has Been Answered

Prostate cancer patients may avoid postoperative radiotherapy according to RADICALS-RT results presented by Parker and colleagues at the European Society for Medical Oncology (ESMO) Congress 2019. The study addresses prostate cancer surgery and whether subsequent radiotherapy has benefits outweighing side effects, a long-standing question.
RADICALS-RT is a clinical trial, the largest postoperative radiotherapy study in prostate cancer to date. Between men routinely receiving radiotherapy shortly after surgery and those receiving it when cancer recurred, at 5 years there was no difference in disease recurrence rate between groups.
RADICALS-RT Clinical Trial
The study enrolled men undergoing prostate cancer surgery in England, Denmark, Canada and Ireland, totaling 1.396 patients. They were randomized to postoperative radiotherapy or standard observation (active follow-up), keeping radiotherapy as an option if disease recurred.
- With median follow-up of 5 years, progression-free survival was 85% in the radiotherapy group and 88% with standard care.
- At year 1 after surgery, incontinence rates were 5,3% with radiotherapy and 2,7% with standard care, a statistically significant difference.
- Longer follow-up is needed for overall and distant metastasis-free survival data.
Results from another study, the ARTISTIC meta-analysis, confirmed RADICALS findings favoring observation over early postoperative radiotherapy.
The findings show radiotherapy is equally effective regardless of whether given shortly after surgery or later for recurrent disease. Strong evidence now supports observation as the standard postoperative approach, reserving radiotherapy for recurrence.
The good news is that many men will avoid radiotherapy side effects, including urine leakage and urinary tract narrowing that may make urination difficult. Both may occur after surgery alone, but radiotherapy increases the risk.
The ARTISTIC meta-analysis, combining 3 studies and 2.151 patients, found that adjuvant radiotherapy had no evidence of improving event-free survival compared with salvage radiotherapy after recurrence.
These are the first results suggesting postoperative prostate cancer radiotherapy may be omitted or delayed in some patients. This will shorten treatment and improve resource use, since modern radiotherapy is technically complex and expensive. Close follow-up will, however, be necessary to identify patients requiring salvage radiotherapy.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.